Back to Miscellaneous News
Verenium Appoints Alexander A. Fitzpatrick General Counsel
Monday, November 08, 2010
Cambridge, MA -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced the appointment of Alexander A. Fitzpatrick as Senior Vice President and General Counsel. Fitzpatrick will report to Carlos A. Riva, Verenium's President and Chief Executive Officer.
"Alex has extensive experience in the biotechnology industry, as well as specific expertise with intellectual property management, corporate finance, complex technology transactions, and strategic partnerships," Riva said. "He will be a key member of our senior team as we look to accelerate Verenium's growth and build the next leading industrial enzymes company."
In addition to his representation of a variety of biotech and other technology companies, Fitzpatrick has previously served as general counsel with public companies. Prior to joining Verenium, Fitzpatrick was general counsel for Kintera, Inc., a NASDAQ listed public company. At Kintera, he managed all legal affairs for the company and negotiated, structured and managed the sale of the company in a public tender offer transaction to Blackbaud, Inc., where he served in a similar capacity for a major division. Previously, Fitzpatrick was Director of Strategic Transactions at Vivendi Universal Net USA Group, Inc.
Prior to Vivendi, he was a member of the business, corporate and technology departments with the law firms Cooley Godward LLP, Rogers & Wells LLP, and Latham & Watkins LLP. In this capacity he represented publicly traded biotechnology and pharmaceutical companies, including Verenium, in a variety of transactions including numerous collaborations, licensing agreements and financing activity. He led in-depth company evaluations and preparations for patent litigation and advised on biotech company intellectual property and patent disputes. Fitzpatrick also handled numerous merger and acquisition transactions and worked with technology transfer, licensing and acquisition of biotechnology intellectual property.
Fitzpatrick received a J.D. degree from the University of California at Berkeley, and a B.S. degree in mathematics fromGeorgetown University.
Verenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes. Verenium currently sells enzymes developed using its R&D capabilities to industrial customers globally for use in markets including grain and oilseed processing, biofuels, animal health and nutrition and other specialty industrial processes. Verenium has built a world-class R&D organization renowned for its capabilities in the rapid screening, identification, evolution and bioengineering of novel enzymes that act as catalysts for biochemical reactions. The company harnesses the power of nature and uses its unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance. For more information on Verenium, visit http://www.verenium.com.
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.
Back to Miscellaneous News